Title:
眼の感染症および疾患を処置するための組成物および方法
Document Type and Number:
Japanese Patent JP6612247
Kind Code:
B2
Abstract:
The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.
Inventors:
Gordon W. Raleigh
Application Number:
JP2016556881A
Publication Date:
November 27, 2019
Filing Date:
March 11, 2015
Export Citation:
Assignee:
University of Virginia Patent Foundation
International Classes:
G01N33/68; A61K45/00; A61P27/02; A61P31/02; A61P43/00; G01N33/50
Domestic Patent References:
| JP2007537260A | ||||
| JP2013504519A |
Foreign References:
| US20110065189 | ||||
| WO2005119899A2 | ||||
| WO2011034207A1 |
Other References:
STILL, K.M. et al.,Development of Quantitative Sandwich ELISAs for Lacritin and the Lacritin-c Splice Variant in Human Tears,Investigative Ophthamology & Visual Science,2012年 3月,Vol. 53, No. 14,p. 4233
ZHANG, Y. et al.,Targeting of Heparanase-modified Syndecan-1 by Prosecretory Mitogen Lacritin Requires Conserved Core GAGAL plus Heparan and Chondroitin Sulfate as a Novel Hybrid Binding Site That Enhances Selectivity,Journal of Biological Chemistry,2013年 4月,Vol. 288, No. 17,pp. 12090-12101
KARNATI, R. et al.,Lacritin and the tear proteome as natural replacement therapy for dry eye,Experimental Eye Research,2013年,Vol. 117,pp. 39-52
MA, P. et al.,Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin,The journal of cell biology,2006年 9月,Vol. 174, No. 7,pp. 1097-1106
MCKOWN, R.L. et al.,Lacritin and other new proteins of the lacrimal functional unit,Experimental Eye Research,2009年,Vol. 88,pp. 848-858
BOEHM, N. et al.,Alterations in the Tear Proteome of Dry Eye Patients-A Matter of the Clinical Phenotype,Investigative Ophthalmology & Visual Science,2013年 3月,Vol. 54, No. 3,pp. 2385-2392
ZHANG, Y. et al.,Targeting of Heparanase-modified Syndecan-1 by Prosecretory Mitogen Lacritin Requires Conserved Core GAGAL plus Heparan and Chondroitin Sulfate as a Novel Hybrid Binding Site That Enhances Selectivity,Journal of Biological Chemistry,2013年 4月,Vol. 288, No. 17,pp. 12090-12101
KARNATI, R. et al.,Lacritin and the tear proteome as natural replacement therapy for dry eye,Experimental Eye Research,2013年,Vol. 117,pp. 39-52
MA, P. et al.,Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin,The journal of cell biology,2006年 9月,Vol. 174, No. 7,pp. 1097-1106
MCKOWN, R.L. et al.,Lacritin and other new proteins of the lacrimal functional unit,Experimental Eye Research,2009年,Vol. 88,pp. 848-858
BOEHM, N. et al.,Alterations in the Tear Proteome of Dry Eye Patients-A Matter of the Clinical Phenotype,Investigative Ophthalmology & Visual Science,2013年 3月,Vol. 54, No. 3,pp. 2385-2392
Attorney, Agent or Firm:
Takuji Yamada
Aoyama Aoi
Michiko Matsutani
Aoyama Aoi
Michiko Matsutani